摘要
目的探讨^(11)C-胆碱PET/CT显像在前列腺良恶性病变鉴别诊断中的作用。方法前列腺病变患者45例,按体重静脉注射7．4 MBq/kg^(11)C-胆碱5 min后行仰卧位盆腔PET/CT显像,可疑转移患者行全身显像。测量前列腺病灶(靶)及肌肉(非靶)组织的最高标准摄取值(SUV_(max)),并计算其比值(P/M)。结果病理检查证实前列腺良性病变27例,前列腺癌18例。前列腺良恶性病变的P/M比值间差异有显著性(1．87±1．21与4．02±1．88,t=2．07,P＜0．01)。以P/M比值＞2．32为标准,^(11)C-胆碱PET/CT显像诊断前列腺癌的灵敏度为88．89%,特异性为88．89%,阴性预测值为92．31%。结论^(11)C-胆碱PET/CT显像是一种诊断前列腺癌较好的无创性检查方法;P/M比值比SUV能更好鉴别前列腺良恶性病变。
Objective To investigate the potential of ^11C-choline PET/CT imaging for differentiating prostate cancer from benign prostate hyperplasia. Methods A total of 45 patients with prostate lesions underwent ^11C-choline PET/CT imaging before transrectal needle biopsy. PET/CT imaging was performed 5 rain after injection of 7.4 MBq/kg ^11C-choline in supine position over lower abdomen （3 min per bed with 2 beds） , including the pelvis, and the whole body with 6 beds when necessary. After attenuation correction and iterative reconstruction, PET data were analyzed semi-quantitatively by measuring maximum standardized uptake values （SUVmax ） in prostate lesions （P, target） and the muscles （ M, non-target） and then P/M ratios were calculated. Also visual analysis was performed in different transverse, sagittal views and slices as well as three-dimensional images. Resdts Eighteen prostate cancer and 27 benign prostate hyperplasia [ and（or） chronic prostatitis] were all confirmed by pathology. The mean P/M ratio of prostate cancer was 4.02 ±1.88, while in benign lesions was 1.87 ± 1.21. The statistical differences of P/M ratios between them were significant （ t = 2.07, P 〈0.01 ）. Using P/M ratio of 2.32 as criterion, the sensitivity, specificity and neg- ative predictive value of ^11C-choline PET/CT imaging were 88.89% , 88.89% and 92.31% respectively. Conclusions ^11C-choline PET/CT imaging is a valuable non-invasive technology in the diagnosis of prostate cancer. The P/M ratio can differentiate prostate cancer from benign lesions better than SUV.
出处
《中华核医学杂志》
CAS
CSCD
北大核心
2006年第6期349-352,共4页
Chinese Journal of Nuclear Medicine
基金
山东省科技发展计划基金(2004GG2202140)
